Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.

被引：4
|
作者：
Caffo, Orazio
Bria, Emilio
De Giorgi, Ugo
Tucci, Marcello
Galli, Luca
Fratino, Lucia
Rossetti, Sabrina
Iacovelli, Roberto
Lo Re, Giovanni
Mosillo, Claudia
Gasparro, Donatello
Guglielmini, Pamela Francesca
Damiani, Azzurra
Procopio, Giuseppe
De Lisi, Delia
Ruatta, Fiorella
Scagliarini, Sarah
Donini, Maddalena
Sperduti, Isabella
Basso, Umberto
机构：
[1] Santa Chiara Hosp, Med Oncol, Trento, Italy
[2] Univ Verona, Verona, Italy
[3] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy
[4] San Luigi Hosp, Orbassano, Italy
[5] Azienda Osped Univ Pisana, Pisa, Italy
[6] Natl Canc Ctr CRO, Aviano, Italy
[7] Ist Nazl Tumori Fdn G Pascale IRCCS, Div Med Oncol, Dept Uro Gynaecol Oncol, Naples, Italy
[8] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, Verona, Italy
[9] Santa Maria Angeli Gen Hosp, Pordenone, Italy
[10] Sapienza Univ Rome, Policlin Umberto 1, Rome, Italy
[11] Azienda Osped Univ Parma, Parma, Italy
[12] SS Antonio & Biagio & Cesare Arrigo Gen Hosp, Oncol, Alessandria, Italy
[13] Azienda Osped Univ San Martino, Genoa, Italy
[14] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[15] Campus Bio Med Univ Rome, Dept Med Oncol, Rome, Italy
[16] Fdn Piemonte Oncol IRCCS, Med Oncol, Candiolo, Italy
[17] Cardarelli Hosp, Naples, Italy
[18] Osped Cremona, SC Oncol, Cremona, Italy
[19] Regina Elena Inst Canc Res, Biostat Unit, Rome, Italy
[20] Ist Oncol Veneto IOV IRCCS, Dept Clin & Expt Oncol, Med Oncol Unit, Padua, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.5030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5030
引用
收藏
页数：5
相关论文
共 50 条
  • [31] When the time matters: Metastatic Castration Resistant Prostate Cancer (mCRPC) patients long responders to Abiraterone acetate (AA) in post-docetaxel setting
    Procopio, G.
    Porcu, L.
    Grassi, P.
    De Giorgi, U.
    Galli, L.
    Caffo, O.
    Boccardo, F.
    Facchini, G.
    De Vincenzo, F.
    Zaniboni, A.
    Chiuri, V.
    Fratino, L.
    Santini, D.
    Adamo, V.
    De Vivo, R.
    Di Nota, A.
    Messina, C.
    Ricotta, R.
    de Braud, F.
    Verzoni, E.
    ANNALS OF ONCOLOGY, 2015, 26 : 59 - 59
  • [32] Circulating tumour cells (CTC) count and prostate-specific antigen (PSA) response measures in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (Doc)
    Lozano Mejorada, R.
    Lorente, D.
    Castro, E.
    Bianchini, D.
    Nombela, P.
    Sandhu, S. K.
    Romero Laorden, N.
    Cendon, Y.
    Sharp, A.
    Almagro Casado, E.
    Pacheco, M. I.
    Rescigno, P.
    Llacer, C.
    Saez, M.
    Rivera, L.
    Vitrone, F.
    Moreno, C.
    Mateo, J.
    de Bono, J. S.
    Olmos Hidalgo, D.
    ANNALS OF ONCOLOGY, 2019, 30 : 350 - 350
  • [33] Survival outcomes from a cumulative analysis from worldwide observational studies on sequential use of new agents (NAs) in metastatic castration-resistant prostate cancer (mCRPC) (CASTOR study).
    Caffo, Orazio
    Wissing, Michel
    Bianchini, Diletta
    Bergman, Andre M.
    Thomsen, Frederik BirkebAk
    Schmid, Sebastian
    Yu, Evan Y.
    Bournakis, Evangelos
    Sella, Avishay
    Basso, Umberto
    De Giorgi, Ugo
    Tucci, Marcello
    Gelderblom, Hans
    Galli, Luca
    Sperduti, Isabella
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study
    Omrcen, Tomislav
    Eterovic, Davor
    Vrdoljak, Eduard
    ANTI-CANCER DRUGS, 2020, 31 (07) : 742 - 746
  • [35] Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).
    Veccia, Antonello
    Burgio, Salvatore Luca
    Di Lorenzo, Giuseppe
    Ortega, Cinzia
    Scognamiglio, Florinda
    Aieta, Michele
    Zustovich, Fable
    Mattioli, Rodolfo
    Mansueto, Giovanni
    Facchini, Gaetano
    Procopio, Giuseppe
    D'Angelo, Alessandro
    Spizzo, Gilbert
    Donini, Maddalena
    Bortolus, Roberto
    Vicario, Giovanni
    Zucali, Paolo A.
    Basso, Umberto
    Lo Re, Giovanni
    Caffo, Orazio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [36] Rezvilutamide (REZ) plus docetaxel (DOC) in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone (ABI).
    Liu, Zhenhua
    Wei, Qiang
    Feng, Ping
    Jiang, Shusuan
    Luo, Hong
    Liao, Hong
    Yu, Dexin
    Chen, Zhiwen
    Zhang, Dahong
    Dai, Tao
    Li, Zeng
    Zhang, Zhiqiang
    Bai, Hong
    Liu, Feng
    Wang, Wenliang
    Lin, Jiaqin
    Wang, Yike
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] CABAZITAXEL PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) PREVIOUSLY TREATED WITH DOCETAXEL: ANALYSIS BY AGE GROUP
    Parente, P.
    Malik, Z.
    di Lorenzo, G.
    Bracarda, S.
    Ardavanis, A.
    Basaran, M.
    de Schultz, W.
    Saad, F.
    van Oort, I.
    Gerritsen, W. R.
    Anton Aparicio, L. M.
    Matus, G.
    Hitier, S.
    Heidenreich, A.
    Bahl, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 61 - 61
  • [38] Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
    Antonarakis, Emmanuel S.
    Rodriguez, Jose Maria M. Piulats
    Gross-Goupil, Marine
    Goh, Jeffrey C.
    Vaishampayan, Ulka N.
    De Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Haiyan
    Kim, Jeri
    Schloss, Charles
    Qiu, Ping
    Suttner, Leah
    Cristescu, Razvan
    Marton, Matthew John
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] CETUXIMAB IN COMBINATION WITH DOCETAXEL IN PATIENTS (PTS) WITH METASTATIC CASTRATION RESISTANT (MCRPC) AND DOCETAXEL-REFRACTORY PROSTATE CANCER: FINAL ANALYSIS OF THE MULTICENTER PHASE II TRIAL SAKK 08/07
    Cathomas, R.
    Rothermundt, C.
    von Moos, R.
    Betticher, D. C.
    Winterhalder, R.
    Droege, C.
    Siciliano, D.
    Berthold, D. R.
    Pless, M.
    Gillessen, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 276 - 276
  • [40] Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting.
    Oh, William K.
    Miao, Raymond
    Duh, Mei Sheng
    Vekeman, Francis
    Sung, Jennifer
    Cheng, Wendy Y.
    Hennessy, Daniel
    Gauthier-Loiselle, Marjolaine
    Fortier, Jonathan
    Dhawan, Ravinder
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345